{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:50:25Z","timestamp":1787161825562,"version":"build-2736575974"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Multiple myeloma (MM) with central nervous system (CNS) involvement is rare with only 1% incidence. So far, there is no standard or effective treatment for CNS MM, and the expected survival time is fewer than 6 months. Here, we report a case of MM with CNS involvement presented with cauda equina syndrome (CES) who achieved complete remission after anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T (CAR-T) cell therapy (Chictr.org.cn, ChiCTR1800017404). The expansion of BCMA CAR-T cells was observed in both peripheral blood (PB) and cerebrospinal fluid (CSF). The CAR-T cells peaked at 2.4 \u00d7 10\n                    <jats:sup>6<\/jats:sup>\n                    \/l in CSF at day 8 and 4.1 \u00d7 10\n                    <jats:sup>9<\/jats:sup>\n                    \/l in PB at day 13. The peak concentration of interleukin (IL)-6 in CSF was detected 3 days earlier, and almost five times higher than that in PB. Next, morphological analysis confirmed the elimination of nucleated cells in CSF 1 month after CAR-T cell treatment from 300 cells\/\u03bcl, and the patient achieved functional recovery with regressed lesion shown in PET-CT. The case demonstrated that BCMA CAR-T cells are effective and safe in this patient population.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2021.755584","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T02:08:20Z","timestamp":1637114900000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome\u2014A Wandering Road to Remission"],"prefix":"10.3389","volume":"11","author":[{"given":"Yiyun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine Tan Su","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiyun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.248518","article-title":"Multiple Myeloma With Central Nervous System Relapse","volume":"105","author":"Egan","year":"2020","journal-title":"Haematologica"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0609.2007.00956.x","article-title":"Central Nervous System Myelomatosis: Review of the Literature","volume":"80","author":"Nieuwenhuizen","year":"2008","journal-title":"Eur J Haematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.08.010","article-title":"Myelomatous Involvement of the Central Nervous System","volume":"16","author":"Paludo","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24351","article-title":"Central Nervous System Involvement by Multiple Myeloma: A Multi-Institutional Retrospective Study of 172 Patients in Daily Clinical Practice","volume":"91","author":"Jurczyszyn","year":"2016","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.11.004","article-title":"Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma","volume":"14","author":"Abdallah","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26447","article-title":"Extramedullary Intracranial Localization of Multiple Myeloma and Treatment With Novel Agents: A Retrospective Survey of 50 Patients","volume":"118","author":"Gozzetti","year":"2012","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T Cells Expressing CD19 Chimeric Antigen Receptors for Acute Lymphoblastic Leukaemia in Children and Young Adults: A Phase 1 Dose-Escalation Trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric Antigen Receptor T Cells Persist and Induce Sustained Remissions in Relapsed Refractory Chronic Lymphocytic Leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric Antigen Receptor T-Cell Therapy \u2014 Assessment and Management of Toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000686","article-title":"Neurotoxicity Associated With Cancer Immunotherapy: Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy","volume":"32","author":"Perrinjaquet","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11940-019-0580-3","article-title":"Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment","volume":"21","author":"Rice","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","article-title":"Predominant Cerebral Cytokine Release Syndrome in CD19-Directed Chimeric Antigen Receptor-Modified T Cell Therapy","volume":"9","author":"Hu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti\u2013B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903","article-title":"T Cells Expressing an Anti\u2013B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Multiple Myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397","article-title":"B Cell Maturation Antigen-Specific CAR T Cells Are Clinically Active in Multiple Myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B Cell Maturation Antigen, in Patients With Relapsed or Refractory Multiple Myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol.J Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory Trial of a Biepitopic CAR T-Targeting B Cell Maturation Antigen in Relapsed\/Refractory Multiple Myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e12888","DOI":"10.7759\/cureus.12888","article-title":"Cauda Equina Syndrome as the Initial Presentation of Concurrent Plasmacytoma and Multiple Myeloma","volume":"13","author":"Pisklakova","year":"2021","journal-title":"Cureus"},{"key":"B21","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2017"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T Cells of Defined CD4+:CD8+ Composition in Adult B Cell ALL Patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"B24","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of Non-Hodgkin\u2019s Lymphoma With a Defined Ratio of CD8 + and CD4 + CD19-Specific Chimeric Antigen Receptor\u2013Modified T Cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.552429","article-title":"Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1158\/2326-6066.CIR-20-0236","article-title":"The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity Against Both Central Nervous System and Systemic Lymphoma","volume":"9","author":"Wang","year":"2021","journal-title":"Cancer Immunol Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.755584\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T02:08:22Z","timestamp":1637114902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.755584\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":26,"alternative-id":["10.3389\/fonc.2021.755584"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.755584","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]},"article-number":"755584"}}